David Reardon, MD
Advertisement
Articles by David Reardon, MD
David Reardon, MD, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma.
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, discusses the ReACT study, which examined the rindopepimut vaccine (CDX-110) plus bevacizumab in patients with relapsed glioblastoma.
Advertisement
Latest Updated Articles
Dr. Reardon on the KEYNOTE-028 Trial of Pembrolizumab for GBMPublished: November 19th 2016 | Updated:
Dr. Reardon Discusses Rindopepimut Plus Bevacizumab in GlioblastomaPublished: November 15th 2014 | Updated:
Dr. Reardon on Updated Data From the Phase II ReACT TrialPublished: November 20th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5